Brief: Vbi Vaccines Presents Additional Phase 1/2A Data From Vbi-1901 In Recurrent GBM At The 2022 Society For Neuro-Oncology (Sno) Annual Meeting
22/11/2022 13:15
Nov 22 (Reuters) - VBI Vaccines Inc VBIV.O :
* VBI VACCINES PRESENTS ADDITIONAL PHASE 1/2A DATA FROM
VBI-1901
IN RECURRENT GBM AT THE 2022 SOCIETY FOR NEURO-ONCOLOGY (SNO)
ANNUAL MEETING
Source text for Eikon: ID:nBw4XH0Xxa
Further company coverage: VBIV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on VBI Vaccines
See all newsBrief: VBI Vaccines Provides Update On Its Restructuring Proceedings
Brief: Vbi Vaccines Announces New Tumor Response Data From Ongoing Randomized Controlled Phase 2B Study Of Vbi-1901 In Recurrent Glioblastoma Patients
VBI Vaccines Inc reports results for the quarter ended in March - Earnings Summary
Brief: VBI Vaccines Says Entered At Market Offering Deal For Gross Proceeds Of Up To $8.5 Mln
Brief: VBI Vaccines Q1 Adjusted EPS USD -0.55